Cycle scheduling for in vitro fertilization with oral contraceptive pills versus oral estradiol valerate: a randomized, controlled trial

BACKGROUND: Both oral contraceptive pills (OCPs) and estradiol (E(2)) valerate have been used to schedule gonadotropin-releasing hormone (GnRH) antagonist in vitro fertilization (IVF) cycles and, consequently, laboratory activities. However, there are no studies comparing treatment outcomes directly between these two pretreatment methods. This randomized controlled trial was aimed at finding differences in ongoing pregnancy rates between GnRH antagonist IVF cycles scheduled with OCPs or E(2) valerate. METHODS: Between January and May 2012, one hundred consecutive patients (nonobese, regularly cycling women 18–38 years with normal day 3 hormone levels and <3 previous IVF/ICSI attempts) undergoing IVF with the GnRH antagonist protocol were randomized to either the OCP or E(2) pretreatment arms, with no restrictions such as blocking or stratification. Authors involved in data collection and analysis were blinded to group assignment. Fifty patients received OCP (30 μg ethinyl E(2)/150 μg levonorgestrel) for 12–16 days from day 1 or 2, and stimulation was started 5 days after stopping OCP. Similarly, 50 patients received 4 mg/day oral E(2) valerate from day 20 for 5–12 days, until the day before starting stimulation. RESULTS: Pretreatment with OCP (mean±SD, 14.5±1.7 days) was significantly longer than with E(2) (7.8±1.9 days). Stimulation and embryological characteristics were similar. Ongoing pregnancy rates (46.0% vs. 44.0%; risk difference, –2.0% [95% CI –21.2% to 17.3%]), as well as implantation (43.5% vs. 47.4%), clinical pregnancy (50.0% vs. 48.0%), clinical miscarriage (7.1% vs. 7.7%), and live birth (42.0% vs. 40.0%) rates were comparable between groups. CONCLUSIONS: This is the first study to directly compare these two methods of cycle scheduling in GnRH antagonist cycles. Our results fail to show statistically significant differences in ongoing pregnancy rates between pretreatment with OCP and E(2) for IVF with the GnRH antagonist protocol. Although the study is limited by its sample size, our results may contribute to a future meta-analysis. An interesting future direction would be to extend our study to women with decreased ovarian reserve, as these are the patients in whom an increase in oocyte yield—due to the hypothetical beneficial effect of steroid pretreatment on follicular synchronization—could more easily be demonstrated. TRIAL REGISTRATION: ClinicalTrials.gov http://NCT01501448

Molecular elucidation of CO2 methanation over a highly active, selective and stable LaNiO3/CeO2-derived catalyst by in situ FTIR and NAP-XPS

The CO2 methanation mechanism over the highly active (TOF=75.1 h−1), selective (>92%) and stable 10% LaNiO3/CeO2-derived catalyst is still unresolved. The surface of the catalyst is monitored under hydrogenation (H2), oxidizing (CO2) and CO2 methanation (H2 +CO2) conditions by near ambient pressure X-ray photoelectron spectroscopy (NAP-XPS) using synchrotron radiation. Meanwhile, the main reaction intermediates are identified by in situ FTIR analysis. NAP-XPS experiments confirm that LaNiO3 perovskite reduction leads to the ex-solution of Ni0 nanoparticles and Ni2+single bondCeO2−x and Ni2+single bondLa2O3 interfaces conformation, favouring the CO2 adsorption and the H2 dissociation/transfer. In situ FTIR experiments combined with the C1s spectra (NAP-XPS) suggest that the CO2 activation occurs on CeO2−x (oxygen vacancies and OH–) at low temperatures, in the form of bicarbonates; whereas, mono-/bidentate carbonates are formed on different strength La2O3 sites at increasing temperatures. These species are consecutively reduced to formates, as the main reaction intermediate, and methane by the H spilled from Ni0 nanoparticles near to NiOsingle bondCeO2−x and NiOsingle bondLa2O3 interfaces.Support for this study was provided by Projects PID2019–105960RB-C21 and PID2019–105960RB-C22 by MCIN/AEI/10.13039/501100011033, the Basque Government (Project IT1509–2022), Generalitat Valenciana (CIPROM/2021/74) and ALBA synchrotron. One of the authors (JAOC) acknowledges the postdoctoral research grant (DOCREC20/49) provided by the University of the Basque Country (UPV/EHU)

Monitoring by in situ NAP-XPS of active sites for CO2 methanation on a Ni/CeO2 catalyst

Ni/CeO2 catalysts are very active and selective for total hydrogenation of CO2 to methane, but the nature of the active sites is still unclear. The surface of a Ni/CeO2 catalyst has been monitored under CO2 methanation conditions by Near Ambient Pressure-XPS (NAP-XPS) using synchrotron radiation, and has been concluded that the species involved in the redox processes taking place during the CO2 methanation mechanism are the Ni2+-CeO2/Ni0 and Ce4+/Ce3+ pairs. In addition, a small fraction of nickel is present on the catalyst surface forming NiO and Ni2+-carbonates/hydroxyls (around 20% of the total surface nickel), but these species do not participate in the redox processes of the methanation mechanism. Under CO2 methanation conditions the H2 reduction rate of the Ni2+-CeO2/Ni0 and Ce4+/Ce3+ couples is much faster than their CO2 reoxidation rate (2 times faster, at least, at 300ºC), but a certain proportion of nickel always remains oxidized under reaction conditions. The high activity of Ni/CeO2 catalysts for CO2 methanation is tentatively attributed to the simultaneous presence of Ni2+-CeO2 and Ni0 active sites where CO2 and H2 are expected to be efficiently dissociated, respectively.Generalitat Valenciana, Spain (PROMETEO/2018/0765) Ministry for Science and Innovation MICINN, Spain (Projects PID2019-105960RB-C21 and PID2019-105960RB-C22) Junta de Andalucía, Spain (Project P18-RTJ-2974); European Union’s Horizon 2020 Research and Innovation Program (Marie Skłodowska-Curie grant agreement No 713567) Science Foundation Ireland Research Centre, Ireland (award 12/RC/2278_P2) ALBA synchrotron, Spain (Proposal number: ID 2020094556)

Personalized ovarian stimulation for assisted reproductive technology : study design considerations to move from hype to added value for patients

Peer reviewedPublisher PD

Influence of Polymorphisms Involved in Platelet Activation and Inflammatory Response on Aspirin-Related Upper Gastrointestinal Bleeding: A Case-Control Study

Background: Despite the wide benefits of aspirin and its cost-effectiveness, aspirin prescriptions have been reduced due to idiosyncratic responses in susceptible individuals. Low-dose aspirin and single-nucleotide polymorphisms (SNPs) are independently associated with increased risk of gastrointestinal hemorrhage; however, to-date, no studies investigated the SNP-aspirin interaction effect on upper gastrointestinal hemorrhage (UGIH). Therefore, we aimed to evaluate the role of 25 SNPs in multiple genes involved in platelet activation, angiogenesis and inflammatory response in aspirin-related UGIH. Methods: A multicenter, full case-control study was conducted in patients exposed and unexposed to aspirin. Three hundred twenty-six cases diagnosed with UGIH were matched with 748 controls (1:3) by age, gender, health center, and recruitment date. Only adults of European origin were included. Participants were stratified by aspirin exposure and genotype [(Aspirin(-), wild-type), (Aspirin(+), wild-type), (Aspirin(+), genetic variation), (Aspirin(-), genetic variation)]. For each SNP, the Odds Ratio of UGIH and their 95% confidence intervals were estimated in each subgroup by using the generalized linear mixed models for dependent binomial variables. SNP-aspirin interaction effect was estimated through Relative Excess Risk due to Interaction (RERI) measures. Results: We observed two categories of SNPs that might modify the risk magnitude of UGIH in aspirin consumers. Seven SNPs (rs1387180 A > G, rs2238631 T > C, rs1799964 T > C, rs5050 T > C/T > G, rs689466 T > C, rs1799983 T > A/T > G, and rs7756935 C > A) were "positive modifiers" associated with an excess of risk from aspirin exposure and carrying that genetic variation (1.75 T, rs1131882 G > A, rs4311994 C > T, rs10120688 G > A, rs4251961 T > C, rs3778355 G > C, rs1330344 C > T, rs5275 A > G/A > T, and rs3779647 C > T) were "negative modifiers" and associated with a reduced risk in aspirin users (-2.74 </= RERI </= -0.95). Conclusion: This preliminary study suggests that polymorphisms in genes involved in platelets activity, angiogenesis and inflammatory response might modify the risk of aspirin-related UGIH. Further studies with larger sample size and in different populations are needed to confirm our findings. If confirmed, this might have great impact on public health, thanks to aspirin's prophylactic properties in diseases of high incidence and severity

Antigen Identification for Orphan T Cell Receptors Expressed on Tumor-Infiltrating Lymphocytes

The immune system can mount T cell responses against tumors; however, the antigen specificities of tumor-infiltrating lymphocytes (TILs) are not well understood. We used yeast-display libraries of peptide-human leukocyte antigen (pHLA) to screen for antigens of “orphan” T cell receptors (TCRs) expressed on TILs from human colorectal adenocarcinoma. Four TIL-derived TCRs exhibited strong selection for peptides presented in a highly diverse pHLA-A∗02:01 library. Three of the TIL TCRs were specific for non-mutated self-antigens, two of which were present in separate patient tumors, and shared specificity for a non-mutated self-antigen derived from U2AF2. These results show that the exposed recognition surface of MHC-bound peptides accessible to the TCR contains sufficient structural information to enable the reconstruction of sequences of peptide targets for pathogenic TCRs of unknown specificity. This finding underscores the surprising specificity of TCRs for their cognate antigens and enables the facile identification of tumor antigens through unbiased screening

Strategies to design clinical studies to identify predictive biomarkers in cancer research

The discovery of reliable biomarkers to predict efficacy and toxicity of anticancer drugs remains one of the key challenges in cancer research. Despite its relevance, no efficient study designs to identify promising candidate biomarkers have been established. This has led to the proliferation of a myriad of exploratory studies using dissimilar strategies, most of which fail to identify any promising targets and are seldom validated. The lack of a proper methodology also determines that many anti-cancer drugs are developed below their potential, due to failure to identify predictive biomarkers. While some drugs will be systematically administered to many patients who will not benefit from them, leading to unnecessary toxicities and costs, others will never reach registration due to our inability to identify the specific patient population in which they are active. Despite these drawbacks, a limited number of outstanding predictive biomarkers have been successfully identified and validated, and have changed the standard practice of oncology. In this manuscript, a multidisciplinary panel reviews how those key biomarkers were identified and, based on those experiences, proposes a methodological framework—the DESIGN guidelines—to standardize the clinical design of biomarker identification studies and to develop future research in this pivotal field